董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nicholas Fernandez | 男 | Independent Director | 42 | 未披露 | 1.67 | 2026-08-03 |
| Philip Lemons | 男 | Independent Director | 55 | 未披露 | 未持股 | 2026-08-03 |
| Richard Baek | 男 | Independent Director | 33 | 未披露 | 未持股 | 2026-08-03 |
| Chris Kim | 男 | Chairman of the Board,Chief Executive Officer and Director | 67 | 18.33万美元 | 961.83 | 2026-08-03 |
| Eun Sook Lee | 女 | Independent Director | 64 | 未披露 | 未持股 | 2026-08-03 |
| Ji Yeon Baek | 女 | Independent Director | 54 | 未披露 | 未持股 | 2026-08-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chris Kim | 男 | Chairman of the Board,Chief Executive Officer and Director | 67 | 18.33万美元 | 961.83 | 2026-08-03 |
| Scott Dam | 男 | Chief Financial Officer | 47 | 未披露 | 未持股 | 2026-08-03 |
| Byong Yoo | 男 | Chief Science Officer | 54 | 未披露 | 未持股 | 2026-08-03 |
| Beom K. Choi | 男 | Chief Technology Officer | 54 | 未披露 | 342.65 | 2026-08-03 |
| Sang jin Daniel Lee | 男 | Head of Research & Development | 58 | 未披露 | 未持股 | 2026-08-03 |
董事简历
中英对照 | 中文 | 英文- Nicholas Fernandez
-
Nicholas Fernandez担任Jatt III Acquisition Corp的首席财务官。Fernandez先生在运营、会计和财务方面拥有超过20年的经验。Fernandez先生于2019年12月至2025年12月任职于对冲基金Athanor Capital，最近担任首席运营官和首席财务官。2024年4月至2024年11月，Fernandez先生担任EcoBridge Capital Management的首席运营官、首席财务官和首席合规官。此前，他于2017年2月至2019年4月担任全球大括号投资银行Jefferies LLC资产管理和另类投资部的首席财务官。在此之前，Fernandez先生曾以多种身份在多家另类投资管理公司工作，从基金会计师晋升为财务总监/运营总监。他的公共会计职业生涯始于安永在纽约的金融服务办公室，在他们的资产管理实践中专注/服务于对冲、私募股权和风险基金，以及咨询。Fernandez先生此前曾从2023年5月起担任Iris Acquisition Corp的董事，直至2025年4月与Liminatus Pharma，LLC进行业务合并，此后一直担任合并后公司Liminatus Pharma，Inc.的董事。Fernandez先生还自2026年1月起担任Amanat Acquisition Corp.的首席财务官，自2026年1月起担任JATT II Acquisition Corp.的首席财务官。Fernandez先生在SUNY奥尔巴尼大学获得会计和金融学士学位，辅修工商管理。Fernandez先生在纽约州持有有效的注册会计师执照。
Nicholas Fernandez serves as Jatt Iii Acquisition Corp's Chief Financial Officer. Mr. Fernandez has over 20 years of experience across operations, accounting and finance. Mr. Fernandez has been with Athanor Capital, a hedge fund, from December 2019 to December 2025, most recently serving as Chief Operating Officer and Chief Financial Officer. From April 2024 to November 2024, Mr. Fernandez served as the Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer of EcoBridge Capital Management. Previously, he was the Chief Financial Officer of the Asset Management and Alternative Investments Divisions of Jefferies LLC, a global bulge bracket investment bank, from February 2017 to April 2019. Prior to that, Mr. Fernandez worked at a variety of alternative investment managers in several capacities, progressing from a Fund Accountant to a Controller/Director of Operations. He started his career in public accounting with Ernst & Young in their Financial Services Office in New York, in their asset management practice with a concentration/serving Hedge, Private Equity and Venture Funds, as well as consulting. Mr. Fernandez has previously served as a director of Iris Acquisition Corp from May 2023 until its business combination with Liminatus Pharma, LLC in April 2025, and has been serving as a director of Liminatus Pharma, Inc., the post combination company since then. Mr. Fernandez has also been serving as the CFO of Amanat Acquisition Corp. since January 2026 and as the CFO of JATT II Acquisition Corp since January 2026. Mr. Fernandez earned a BS in Accounting and Finance with a minor in Business Administration from the University at Albany, SUNY. Mr. Fernandez holds an active Certified Public Accountant License in the state of New York. - Nicholas Fernandez担任Jatt III Acquisition Corp的首席财务官。Fernandez先生在运营、会计和财务方面拥有超过20年的经验。Fernandez先生于2019年12月至2025年12月任职于对冲基金Athanor Capital，最近担任首席运营官和首席财务官。2024年4月至2024年11月，Fernandez先生担任EcoBridge Capital Management的首席运营官、首席财务官和首席合规官。此前，他于2017年2月至2019年4月担任全球大括号投资银行Jefferies LLC资产管理和另类投资部的首席财务官。在此之前，Fernandez先生曾以多种身份在多家另类投资管理公司工作，从基金会计师晋升为财务总监/运营总监。他的公共会计职业生涯始于安永在纽约的金融服务办公室，在他们的资产管理实践中专注/服务于对冲、私募股权和风险基金，以及咨询。Fernandez先生此前曾从2023年5月起担任Iris Acquisition Corp的董事，直至2025年4月与Liminatus Pharma，LLC进行业务合并，此后一直担任合并后公司Liminatus Pharma，Inc.的董事。Fernandez先生还自2026年1月起担任Amanat Acquisition Corp.的首席财务官，自2026年1月起担任JATT II Acquisition Corp.的首席财务官。Fernandez先生在SUNY奥尔巴尼大学获得会计和金融学士学位，辅修工商管理。Fernandez先生在纽约州持有有效的注册会计师执照。
- Nicholas Fernandez serves as Jatt Iii Acquisition Corp's Chief Financial Officer. Mr. Fernandez has over 20 years of experience across operations, accounting and finance. Mr. Fernandez has been with Athanor Capital, a hedge fund, from December 2019 to December 2025, most recently serving as Chief Operating Officer and Chief Financial Officer. From April 2024 to November 2024, Mr. Fernandez served as the Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer of EcoBridge Capital Management. Previously, he was the Chief Financial Officer of the Asset Management and Alternative Investments Divisions of Jefferies LLC, a global bulge bracket investment bank, from February 2017 to April 2019. Prior to that, Mr. Fernandez worked at a variety of alternative investment managers in several capacities, progressing from a Fund Accountant to a Controller/Director of Operations. He started his career in public accounting with Ernst & Young in their Financial Services Office in New York, in their asset management practice with a concentration/serving Hedge, Private Equity and Venture Funds, as well as consulting. Mr. Fernandez has previously served as a director of Iris Acquisition Corp from May 2023 until its business combination with Liminatus Pharma, LLC in April 2025, and has been serving as a director of Liminatus Pharma, Inc., the post combination company since then. Mr. Fernandez has also been serving as the CFO of Amanat Acquisition Corp. since January 2026 and as the CFO of JATT II Acquisition Corp since January 2026. Mr. Fernandez earned a BS in Accounting and Finance with a minor in Business Administration from the University at Albany, SUNY. Mr. Fernandez holds an active Certified Public Accountant License in the state of New York.
- Philip Lemons
-
Philip Lemons，自2020年10月起担任ICE Global Consulting， Inc.（临床研究咨询公司）的首席商务官和董事会成员；自2013年7月起担任Nine18 Consulting， LLC的顾问和所有者。他还曾在杜克临床研究所（Duke Clinical Research Institute）、Clintrax Global和Momentum Research担任高级管理职务，在那里他领导临床试验战略、业务发展和国际合作。他持有Guilford College的商业管理学士学位。
Philip Lemons has been a director of Liminatus Pharma, Inc. since July 10, 2025.Mr. Lemons has served as Chief Business Officer and a board member of ICE Global Consulting, Inc., a clinical research consulting company, since October 2020 and as consultant and owner of Nine18 Consulting, LLC since July 2013. Mr. Lemons has also held senior executive positions at Duke Clinical Research Institute, Clintrax Global, and Momentum Research, where he led clinical trial strategy, business development, and international collaborations. Mr. Lemons holds a Bachelor of Science degree in business management from Guilford College. - Philip Lemons，自2020年10月起担任ICE Global Consulting， Inc.（临床研究咨询公司）的首席商务官和董事会成员；自2013年7月起担任Nine18 Consulting， LLC的顾问和所有者。他还曾在杜克临床研究所（Duke Clinical Research Institute）、Clintrax Global和Momentum Research担任高级管理职务，在那里他领导临床试验战略、业务发展和国际合作。他持有Guilford College的商业管理学士学位。
- Philip Lemons has been a director of Liminatus Pharma, Inc. since July 10, 2025.Mr. Lemons has served as Chief Business Officer and a board member of ICE Global Consulting, Inc., a clinical research consulting company, since October 2020 and as consultant and owner of Nine18 Consulting, LLC since July 2013. Mr. Lemons has also held senior executive positions at Duke Clinical Research Institute, Clintrax Global, and Momentum Research, where he led clinical trial strategy, business development, and international collaborations. Mr. Lemons holds a Bachelor of Science degree in business management from Guilford College.
- Richard Baek
-
Richard Baek，曾担任营销和广告代理公司Studio City PXL的副总裁、财务和业务主管。2021年11月至2022年6月，Baek先生在Hawke Media担任财务总监。2021年4月至2021年11月，Baek先生在RAPP（一家Omnicom公司）担任副财务总监。Baek先生拥有旧金山大学企业管理理学学士学位。
Richard Baek has been a director of Liminatus Pharma, Inc. since July 10, 2025. He has demonstrated the ability to ensure adherence to accounting standards and financial regulations. Since December 2022, Mr. Baek has served as Vice President, Head of Finance & Business at Studio City PXL, a marketing and advertising agency. From November 2021 to June 2022, Mr. Baek was Finance Director at Hawke Media. From April 2021 to November 2021, Mr. Baek was Associate Finance Director at RAPP (an Omnicom company). Mr. Baek holds a Bachelor of Science degree in business management from the University of San Francisco. - Richard Baek，曾担任营销和广告代理公司Studio City PXL的副总裁、财务和业务主管。2021年11月至2022年6月，Baek先生在Hawke Media担任财务总监。2021年4月至2021年11月，Baek先生在RAPP（一家Omnicom公司）担任副财务总监。Baek先生拥有旧金山大学企业管理理学学士学位。
- Richard Baek has been a director of Liminatus Pharma, Inc. since July 10, 2025. He has demonstrated the ability to ensure adherence to accounting standards and financial regulations. Since December 2022, Mr. Baek has served as Vice President, Head of Finance & Business at Studio City PXL, a marketing and advertising agency. From November 2021 to June 2022, Mr. Baek was Finance Director at Hawke Media. From April 2021 to November 2021, Mr. Baek was Associate Finance Director at RAPP (an Omnicom company). Mr. Baek holds a Bachelor of Science degree in business management from the University of San Francisco.
- Chris Kim
-
Chris Kim自2018年5月成立以来一直担任Liminat Pharma，LLC的首席执行官和管理成员，并自2022年11月23日起担任Liminat Pharma，Inc.的首席执行官和董事。2016年12月至今，他还担任宾夕法尼亚州费城Viral Gene，Inc.的首席执行官。2007年1月至2017年10月，任中国最大律师事务所德恒律师事务所NY法律顾问。Kim先生在包括专利、商标、版权、商业秘密、不正当竞争等相关领域的知识产权法方面拥有超过30年的经验。Kim先生毕业于宾夕法尼亚大学法学院法学硕士、SJD（C）、并购、企业融资、投资。他完成了Sa d Biness School，University of Oxford，Oxford Entrepreneurship：Venture Finance Program，Certificate，2019 – 2020，和Harvard University Biness School，Entrepreneurs Essentials，Certificate，2018 – 2019。
Chris Kim has been Liminatus Pharma, LLC's Chief Executive Officer and Managing Member since its founding in May 2018 and has been the Chief Executive Officer and Director of Liminatus Pharma, Inc. since November 23, 2022. From December 2016 to the present, he has also served as Chief Executive Officer of Viral Gene, Inc., Philadelphia, PA. From January 2007 to October 2017, he was Counsel for DeHeng Law Office NY, the largest law firm in China. Mr. Kim has over 30 years of experience in intellectual property law including patent, trademark, copyright, trade secret, unfair competition, and other related areas. Mr. Kim is a graduate of University of Pennsylvania Law School, LLM, SJD (C), M&A, Corporate Financing, Investment. He completed Said Business School, University of Oxford, Oxford Entrepreneurship: Venture Finance Programme, Certificate, 2019 – 2020, and the Harvard University Business School, Entrepreneurs Essentials, Certificate, 2018 – 2019. - Chris Kim自2018年5月成立以来一直担任Liminat Pharma，LLC的首席执行官和管理成员，并自2022年11月23日起担任Liminat Pharma，Inc.的首席执行官和董事。2016年12月至今，他还担任宾夕法尼亚州费城Viral Gene，Inc.的首席执行官。2007年1月至2017年10月，任中国最大律师事务所德恒律师事务所NY法律顾问。Kim先生在包括专利、商标、版权、商业秘密、不正当竞争等相关领域的知识产权法方面拥有超过30年的经验。Kim先生毕业于宾夕法尼亚大学法学院法学硕士、SJD（C）、并购、企业融资、投资。他完成了Sa d Biness School，University of Oxford，Oxford Entrepreneurship：Venture Finance Program，Certificate，2019 – 2020，和Harvard University Biness School，Entrepreneurs Essentials，Certificate，2018 – 2019。
- Chris Kim has been Liminatus Pharma, LLC's Chief Executive Officer and Managing Member since its founding in May 2018 and has been the Chief Executive Officer and Director of Liminatus Pharma, Inc. since November 23, 2022. From December 2016 to the present, he has also served as Chief Executive Officer of Viral Gene, Inc., Philadelphia, PA. From January 2007 to October 2017, he was Counsel for DeHeng Law Office NY, the largest law firm in China. Mr. Kim has over 30 years of experience in intellectual property law including patent, trademark, copyright, trade secret, unfair competition, and other related areas. Mr. Kim is a graduate of University of Pennsylvania Law School, LLM, SJD (C), M&A, Corporate Financing, Investment. He completed Said Business School, University of Oxford, Oxford Entrepreneurship: Venture Finance Programme, Certificate, 2019 – 2020, and the Harvard University Business School, Entrepreneurs Essentials, Certificate, 2018 – 2019.
- Eun Sook Lee
-
Eun Sook Lee自2025年4月30日起担任Liminat Pharma，Inc.的董事。自2020年以来，李医生一直是韩国国家癌症中心乳腺癌中心的外科医生。她目前也是韩国国家癌症中心癌症科学与政策研究生院名誉教授。2017年至2020年，她担任韩国国家癌症中心院长。从2017年到2020年，李博士还是国家癌症中心癌症科学与政策研究生院院长。2016年至2017年，她担任国家癌症中心免疫疗法研究项目负责人。李博士在韩国首尔高丽大学研究生院获得医学博士学位。她还获得了医学高丽大学研究生院的医学硕士学位。李博士获得高丽大学医学院学士学位。她是Numero医学协会的董事会成员。
Eun Sook Lee has been a director of Liminatus Pharma, Inc. since April 30, 2025. Since 2020, Dr. Lee has been a surgeon at the Center for Breast Cancer, National Cancer Center, Korea. She is also currently Honorary Professor, Graduate School of Cancer Science and Policy National Cancer Center, Korea. From 2017 to 2020, she was the President of the National Cancer Center, Korea. From 2017 to 2020, Dr. Lee was also President of the National Cancer Center Graduate School of Cancer Science and Policy. From 2016 to 2017, she was the Head of the Program for Immunotherapy Research, National Cancer Center.Dr. Lee received her MD and PhD from Korea University Graduate School, Seoul, Korea. She also received a Master's degree in Medicine from Medicine Korea University Graduate School. Dr. Lee received a Bachelor's Degree from Korea University College of Medicine. She is a board member of numerous medical societies. - Eun Sook Lee自2025年4月30日起担任Liminat Pharma，Inc.的董事。自2020年以来，李医生一直是韩国国家癌症中心乳腺癌中心的外科医生。她目前也是韩国国家癌症中心癌症科学与政策研究生院名誉教授。2017年至2020年，她担任韩国国家癌症中心院长。从2017年到2020年，李博士还是国家癌症中心癌症科学与政策研究生院院长。2016年至2017年，她担任国家癌症中心免疫疗法研究项目负责人。李博士在韩国首尔高丽大学研究生院获得医学博士学位。她还获得了医学高丽大学研究生院的医学硕士学位。李博士获得高丽大学医学院学士学位。她是Numero医学协会的董事会成员。
- Eun Sook Lee has been a director of Liminatus Pharma, Inc. since April 30, 2025. Since 2020, Dr. Lee has been a surgeon at the Center for Breast Cancer, National Cancer Center, Korea. She is also currently Honorary Professor, Graduate School of Cancer Science and Policy National Cancer Center, Korea. From 2017 to 2020, she was the President of the National Cancer Center, Korea. From 2017 to 2020, Dr. Lee was also President of the National Cancer Center Graduate School of Cancer Science and Policy. From 2016 to 2017, she was the Head of the Program for Immunotherapy Research, National Cancer Center.Dr. Lee received her MD and PhD from Korea University Graduate School, Seoul, Korea. She also received a Master's degree in Medicine from Medicine Korea University Graduate School. Dr. Lee received a Bachelor's Degree from Korea University College of Medicine. She is a board member of numerous medical societies.
- Ji Yeon Baek
-
Ji Yeon Baek，自2025年4月30日起担任Liminatus Pharma，Inc.的董事。Baek博士拥有丰富的临床经验，并拥有成功领导结直肠癌和直肠癌有影响力研究的记录。自2024年3月起，Baek博士一直担任高丽大学九老医院的临床教授。从2009年到2024年，白克博士是大韩民国国家癌症中心的研究医学肿瘤学家。2018年至2019年，她是Dana-Farber癌症中心的访问调查员。Baek博士在韩国天主教大学获得医学博士、硕士和博士学位。
Ji Yeon Baek has been a director of Liminatus Pharma, Inc. since April 30, 2025. Dr. Baek has extensive clinical experience, combined with a track record of successfully leading impactful studies in colorectal and rectal cancer. Since March 2024, Dr. Baek has been a clinical professor at Korea University Guro Hospital. From 2009 to 2024, Dr. Baek was a research medical oncologist at National Cancer Center, Republic of Korea. From 2018 to 2019, she was a visiting investigator at Dana Farber Cancer Center. Dr. Baek received her MD, MS and PhD at The Catholic University of Korea. - Ji Yeon Baek，自2025年4月30日起担任Liminatus Pharma，Inc.的董事。Baek博士拥有丰富的临床经验，并拥有成功领导结直肠癌和直肠癌有影响力研究的记录。自2024年3月起，Baek博士一直担任高丽大学九老医院的临床教授。从2009年到2024年，白克博士是大韩民国国家癌症中心的研究医学肿瘤学家。2018年至2019年，她是Dana-Farber癌症中心的访问调查员。Baek博士在韩国天主教大学获得医学博士、硕士和博士学位。
- Ji Yeon Baek has been a director of Liminatus Pharma, Inc. since April 30, 2025. Dr. Baek has extensive clinical experience, combined with a track record of successfully leading impactful studies in colorectal and rectal cancer. Since March 2024, Dr. Baek has been a clinical professor at Korea University Guro Hospital. From 2009 to 2024, Dr. Baek was a research medical oncologist at National Cancer Center, Republic of Korea. From 2018 to 2019, she was a visiting investigator at Dana Farber Cancer Center. Dr. Baek received her MD, MS and PhD at The Catholic University of Korea.
高管简历
中英对照 | 中文 | 英文- Chris Kim
Chris Kim自2018年5月成立以来一直担任Liminat Pharma，LLC的首席执行官和管理成员，并自2022年11月23日起担任Liminat Pharma，Inc.的首席执行官和董事。2016年12月至今，他还担任宾夕法尼亚州费城Viral Gene，Inc.的首席执行官。2007年1月至2017年10月，任中国最大律师事务所德恒律师事务所NY法律顾问。Kim先生在包括专利、商标、版权、商业秘密、不正当竞争等相关领域的知识产权法方面拥有超过30年的经验。Kim先生毕业于宾夕法尼亚大学法学院法学硕士、SJD（C）、并购、企业融资、投资。他完成了Sa d Biness School，University of Oxford，Oxford Entrepreneurship：Venture Finance Program，Certificate，2019 – 2020，和Harvard University Biness School，Entrepreneurs Essentials，Certificate，2018 – 2019。
Chris Kim has been Liminatus Pharma, LLC's Chief Executive Officer and Managing Member since its founding in May 2018 and has been the Chief Executive Officer and Director of Liminatus Pharma, Inc. since November 23, 2022. From December 2016 to the present, he has also served as Chief Executive Officer of Viral Gene, Inc., Philadelphia, PA. From January 2007 to October 2017, he was Counsel for DeHeng Law Office NY, the largest law firm in China. Mr. Kim has over 30 years of experience in intellectual property law including patent, trademark, copyright, trade secret, unfair competition, and other related areas. Mr. Kim is a graduate of University of Pennsylvania Law School, LLM, SJD (C), M&A, Corporate Financing, Investment. He completed Said Business School, University of Oxford, Oxford Entrepreneurship: Venture Finance Programme, Certificate, 2019 – 2020, and the Harvard University Business School, Entrepreneurs Essentials, Certificate, 2018 – 2019.- Chris Kim自2018年5月成立以来一直担任Liminat Pharma，LLC的首席执行官和管理成员，并自2022年11月23日起担任Liminat Pharma，Inc.的首席执行官和董事。2016年12月至今，他还担任宾夕法尼亚州费城Viral Gene，Inc.的首席执行官。2007年1月至2017年10月，任中国最大律师事务所德恒律师事务所NY法律顾问。Kim先生在包括专利、商标、版权、商业秘密、不正当竞争等相关领域的知识产权法方面拥有超过30年的经验。Kim先生毕业于宾夕法尼亚大学法学院法学硕士、SJD（C）、并购、企业融资、投资。他完成了Sa d Biness School，University of Oxford，Oxford Entrepreneurship：Venture Finance Program，Certificate，2019 – 2020，和Harvard University Biness School，Entrepreneurs Essentials，Certificate，2018 – 2019。
- Chris Kim has been Liminatus Pharma, LLC's Chief Executive Officer and Managing Member since its founding in May 2018 and has been the Chief Executive Officer and Director of Liminatus Pharma, Inc. since November 23, 2022. From December 2016 to the present, he has also served as Chief Executive Officer of Viral Gene, Inc., Philadelphia, PA. From January 2007 to October 2017, he was Counsel for DeHeng Law Office NY, the largest law firm in China. Mr. Kim has over 30 years of experience in intellectual property law including patent, trademark, copyright, trade secret, unfair competition, and other related areas. Mr. Kim is a graduate of University of Pennsylvania Law School, LLM, SJD (C), M&A, Corporate Financing, Investment. He completed Said Business School, University of Oxford, Oxford Entrepreneurship: Venture Finance Programme, Certificate, 2019 – 2020, and the Harvard University Business School, Entrepreneurs Essentials, Certificate, 2018 – 2019.
- Scott Dam
Scott Dam自2025年4月30日起担任Liminat Pharma，Inc.的首席财务官。自2020年7月以来，Dam先生一直担任IT和BINES服务的全球创新者NTT Data的信用与市场风险主管。从2018年1月到2020年6月，Dam先生是Thynk Digital的Biness合伙人。Dam先生之前的专业经验包括在美国银行、美林证券和LLS Fargo担任高管，并为全球重要投资银行和私募股权公司的C级客户提供咨询服务。Dam先生获得了皇后大学、McColl Biness学院的MBA学位，以及北卡罗来纳大学夏洛特分校的Biness Administration理学学士学位。他在Cleveland Diabetes Care的董事会任职，并担任财务主管和Hope Haven的董事会成员，Hope Haven是一家位于北卡罗来纳州夏洛特的501（c）3 Non Profit。
Scott Dam has been the Chief Financial Officer of Liminatus Pharma, Inc. since April 30, 2025. Since July 2020, Mr. Dam has been Head of Credit & Market Risk for NTT Data, a global innovator of IT and business services. From January 2018 to June 2020, Mr. Dam was a Business Partner of Thynk Digital. Mr. Dam's prior professional experience includes working as an executive at Bank of America, Merrill Lynch and Wells Fargo and advisory to C Level clients at Global Significant Investment Banks and Private Equity Firms. Mr. Dam received a MBA from Queens University, McColl School of Business, and a Bachelor of Science in Business Administration from the University of North Carolina at Charlotte. He previously served on the Board of Cleveland Diabetes Care and as Treasurer and on the Board of Directors for Hope Haven, a 501(c)3 Non Profit in Charlotte, North Carolina.- Scott Dam自2025年4月30日起担任Liminat Pharma，Inc.的首席财务官。自2020年7月以来，Dam先生一直担任IT和BINES服务的全球创新者NTT Data的信用与市场风险主管。从2018年1月到2020年6月，Dam先生是Thynk Digital的Biness合伙人。Dam先生之前的专业经验包括在美国银行、美林证券和LLS Fargo担任高管，并为全球重要投资银行和私募股权公司的C级客户提供咨询服务。Dam先生获得了皇后大学、McColl Biness学院的MBA学位，以及北卡罗来纳大学夏洛特分校的Biness Administration理学学士学位。他在Cleveland Diabetes Care的董事会任职，并担任财务主管和Hope Haven的董事会成员，Hope Haven是一家位于北卡罗来纳州夏洛特的501（c）3 Non Profit。
- Scott Dam has been the Chief Financial Officer of Liminatus Pharma, Inc. since April 30, 2025. Since July 2020, Mr. Dam has been Head of Credit & Market Risk for NTT Data, a global innovator of IT and business services. From January 2018 to June 2020, Mr. Dam was a Business Partner of Thynk Digital. Mr. Dam's prior professional experience includes working as an executive at Bank of America, Merrill Lynch and Wells Fargo and advisory to C Level clients at Global Significant Investment Banks and Private Equity Firms. Mr. Dam received a MBA from Queens University, McColl School of Business, and a Bachelor of Science in Business Administration from the University of North Carolina at Charlotte. He previously served on the Board of Cleveland Diabetes Care and as Treasurer and on the Board of Directors for Hope Haven, a 501(c)3 Non Profit in Charlotte, North Carolina.
- Byong Yoo
BYong Chul Yoo自2025年4月30日起担任Liminat Pharma，Inc.的首席科学官。自2023年3月以来，Yoo博士一直担任InnoBation Bio Inc.的首席执行官。2019年至2023年，Yoo博士担任大韩民国国家癌症中心转化科学司的首席科学家。2018年至2023年，他还担任大韩民国国家癌症中心癌症科学与政策研究生院癌症生物医学科学系的兼职教授。从2013年到2019年，Yoo博士是大韩民国国家癌症中心研究所大肠癌分会和生物标志物分会的高级科学家。2006年至2013年任结直肠癌分会副科学家。Yoo博士在维也纳大学获得博士学位，维也纳，Atria。他在耶鲁大学做了一年的博士后课程。他在大韩民国研究生院成均馆大学获得理学硕士和理学学士学位。
Byong Yoo has been the Chief Science Officer of Liminatus Pharma, Inc. since April 30, 2025. Since March 2023, Dr. Yoo has been the Chief Executive Officer of InnoBation Bio Inc. From 2019 to 2023, Dr. Yoo was the Principal Scientist at the Division of Translational Science, National Cancer Center, Republic of Korea. From 2018 to 2023, he has also been an Adjunct Professor at Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Republic of Korea. From 2013 to 2019, Dr. Yoo was a Senior Scientist at Colorectal Cancer Branch and the Biomarker Branch, Research Institute, National Cancer Center, Republic of Korea. From 2006 to 2013, he was an Associate Scientist in the Colorectal Cancer Branch.- BYong Chul Yoo自2025年4月30日起担任Liminat Pharma，Inc.的首席科学官。自2023年3月以来，Yoo博士一直担任InnoBation Bio Inc.的首席执行官。2019年至2023年，Yoo博士担任大韩民国国家癌症中心转化科学司的首席科学家。2018年至2023年，他还担任大韩民国国家癌症中心癌症科学与政策研究生院癌症生物医学科学系的兼职教授。从2013年到2019年，Yoo博士是大韩民国国家癌症中心研究所大肠癌分会和生物标志物分会的高级科学家。2006年至2013年任结直肠癌分会副科学家。Yoo博士在维也纳大学获得博士学位，维也纳，Atria。他在耶鲁大学做了一年的博士后课程。他在大韩民国研究生院成均馆大学获得理学硕士和理学学士学位。
- Byong Yoo has been the Chief Science Officer of Liminatus Pharma, Inc. since April 30, 2025. Since March 2023, Dr. Yoo has been the Chief Executive Officer of InnoBation Bio Inc. From 2019 to 2023, Dr. Yoo was the Principal Scientist at the Division of Translational Science, National Cancer Center, Republic of Korea. From 2018 to 2023, he has also been an Adjunct Professor at Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Republic of Korea. From 2013 to 2019, Dr. Yoo was a Senior Scientist at Colorectal Cancer Branch and the Biomarker Branch, Research Institute, National Cancer Center, Republic of Korea. From 2006 to 2013, he was an Associate Scientist in the Colorectal Cancer Branch.
- Beom K. Choi
Beom K. Choi自2025年4月30日起担任Liminat Pharma，Inc.的首席技术官。自2022年以来，Choi博士一直担任位于大韩民国首尔的InnoBation Bio，Inc.的首席技术官。自2022年起，他还担任专注于生物制药功效的Samda BioLab的首席执行官。2018年至2022年，崔博士担任国家癌症中心生物医药生产分中心QA经理。2012年至2017年，任国家癌症中心生物医药生产分中心（T细胞疗法cGMP设施）科长。2011年至2019年，Choi博士担任国家癌症中心癌症免疫学分会高级科学家职务。Choi博士于2005年在韩国蔚山蔚山大学免疫学和生物医学系获得博士学位。在韩国大田汉南大学生命科学学院微生物学系获得理学硕士和理学学士学位。Choi博士是numero研究论文和关于细胞免疫学和vario治疗癌症的文章的作者。
Beom K. Choi has been the Chief Technology Officer of Liminatus Pharma, Inc. since April 30, 2025. Since 2022, Dr. Choi has been Chief Technology Officer for InnoBation Bio, Inc., based in Seoul, Republic of Korea. Since 2022, he has also been the Chief Executive Officer of Samda BioLab, which focuses on the efficacy of biopharmaceuticals. From 2018 to 2022, Dr. Choi was the QA manager, Biomedicine Production Branch, National Cancer Center. From 2012 to 2017, he was the Chief, Biomedicine Production Branch (cGMP facility for T cell therapeutics), National Cancer Center. From 2011 to 2019, Dr. Choi held the position of Senior Scientist, Cancer Immunology Branch, National Cancer Center.Dr. Choi received his PhD in 2005 from Department of Immunology and Biomedicine, University of Ulsan, Ulsan, Korea. He received his Master of Science and Bachelor of Science degrees from the Department of Microbiology, College of Life Science, Hannam University, Daejeon, Korea. Dr. Choi is the author of numerous research papers and articles about cellular immunology and various treatments for cancer.- Beom K. Choi自2025年4月30日起担任Liminat Pharma，Inc.的首席技术官。自2022年以来，Choi博士一直担任位于大韩民国首尔的InnoBation Bio，Inc.的首席技术官。自2022年起，他还担任专注于生物制药功效的Samda BioLab的首席执行官。2018年至2022年，崔博士担任国家癌症中心生物医药生产分中心QA经理。2012年至2017年，任国家癌症中心生物医药生产分中心（T细胞疗法cGMP设施）科长。2011年至2019年，Choi博士担任国家癌症中心癌症免疫学分会高级科学家职务。Choi博士于2005年在韩国蔚山蔚山大学免疫学和生物医学系获得博士学位。在韩国大田汉南大学生命科学学院微生物学系获得理学硕士和理学学士学位。Choi博士是numero研究论文和关于细胞免疫学和vario治疗癌症的文章的作者。
- Beom K. Choi has been the Chief Technology Officer of Liminatus Pharma, Inc. since April 30, 2025. Since 2022, Dr. Choi has been Chief Technology Officer for InnoBation Bio, Inc., based in Seoul, Republic of Korea. Since 2022, he has also been the Chief Executive Officer of Samda BioLab, which focuses on the efficacy of biopharmaceuticals. From 2018 to 2022, Dr. Choi was the QA manager, Biomedicine Production Branch, National Cancer Center. From 2012 to 2017, he was the Chief, Biomedicine Production Branch (cGMP facility for T cell therapeutics), National Cancer Center. From 2011 to 2019, Dr. Choi held the position of Senior Scientist, Cancer Immunology Branch, National Cancer Center.Dr. Choi received his PhD in 2005 from Department of Immunology and Biomedicine, University of Ulsan, Ulsan, Korea. He received his Master of Science and Bachelor of Science degrees from the Department of Microbiology, College of Life Science, Hannam University, Daejeon, Korea. Dr. Choi is the author of numerous research papers and articles about cellular immunology and various treatments for cancer.
- Sang jin Daniel Lee
桑进Daniel Lee自2025年4月30日起担任Liminat Pharma，Inc.研发主管。Lee博士自2017年起担任韩国国家癌症中心免疫科首席科学家。2019年至2021年，李博士担任国家癌症中心癌症免疫科负责人。2014年至今，任癌症科学与政策研究生院教授。从2010年到2016年，李医生担任国家癌症中心生殖癌症分部主任。曾获美国弗吉尼亚州夏洛茨维尔市弗吉尼亚大学哲学博士学位、麦迪逊威斯康辛大学理学硕士学位、韩国首尔国立大学理学学士学位。
Sang jin Daniel Lee has been the Head of Research and Development of Liminatus Pharma, Inc. since April 30, 2025. Dr. Lee has been Principal Scientist, National Cancer Center of Korea, Immunology Division, since 2017. From 2019 to 2021, Dr. Lee was the Head, Cancer Immunology Division, National Cancer Center. From 2014 to the present, he has been a Professor, Graduate School of Cancer Science and Policy. From 2010 to 2016, Dr. Lee was the Chief, Genitourinary Cancer Branch, National Cancer Center.He received a Doctorate of Philosophy from the University of Virginia, Charlottesville, Virginia, a Master of Science from the University of Wisconsin, Madison, and a Bachelor of Science from Seoul National University, Seoul, Korea.- 桑进Daniel Lee自2025年4月30日起担任Liminat Pharma，Inc.研发主管。Lee博士自2017年起担任韩国国家癌症中心免疫科首席科学家。2019年至2021年，李博士担任国家癌症中心癌症免疫科负责人。2014年至今，任癌症科学与政策研究生院教授。从2010年到2016年，李医生担任国家癌症中心生殖癌症分部主任。曾获美国弗吉尼亚州夏洛茨维尔市弗吉尼亚大学哲学博士学位、麦迪逊威斯康辛大学理学硕士学位、韩国首尔国立大学理学学士学位。
- Sang jin Daniel Lee has been the Head of Research and Development of Liminatus Pharma, Inc. since April 30, 2025. Dr. Lee has been Principal Scientist, National Cancer Center of Korea, Immunology Division, since 2017. From 2019 to 2021, Dr. Lee was the Head, Cancer Immunology Division, National Cancer Center. From 2014 to the present, he has been a Professor, Graduate School of Cancer Science and Policy. From 2010 to 2016, Dr. Lee was the Chief, Genitourinary Cancer Branch, National Cancer Center.He received a Doctorate of Philosophy from the University of Virginia, Charlottesville, Virginia, a Master of Science from the University of Wisconsin, Madison, and a Bachelor of Science from Seoul National University, Seoul, Korea.